Management of Cancer-Associated Thrombosis
Authors:
- 10 October 2020
- journal article
- research article
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 22 (11) , 1-13
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN StudyJournal of Thrombosis and Haemostasis, 2015
- Direct Oral Anticoagulants in Patients With VTE and CancerChest, 2015
- Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trialsBlood, 2014
- Epidemiology of cancer-associated venous thrombosisBlood, 2013
- Tumor Grade Is Associated With Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis StudyJournal of Clinical Oncology, 2012
- Risk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-AnalysisPLOS Medicine, 2012
- Outpatient Use of Low Molecular Weight Heparin Monotherapy for First-Line Treatment of Venous Thromboembolism in Advanced CancerThe Oncologist, 2012
- Barriers to the long‐term use of low‐molecular weight heparins for treatment of cancer‐associated thrombosisJournal of Thrombosis and Haemostasis, 2006
- Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with CancerNew England Journal of Medicine, 2003
- Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosisBlood, 2002